The role of pharmacokinetic and pharmacodynamic measurements in the use of direct oral anticoagulants (DOACs)
Date:
23/11/2015
Location:
European Medicines Agency, London, UK
This EMA workshop will bring together experts and stakeholders to discuss the utility of pharmacokinetic (PK) and pharmacodynamic (PD) measurements in the clinical use of the new direct oral anticoagulants (DOACs) and whether those could enhance the benefit-risk profile of these medicines by further reducing the risk of major bleedings while maintaining or improving the protection against thromboembolic events. The objectives of the workshop are to improve the understanding of the clinical use of DOACs, issues in relation to PK and PD measurements as well as priorities in future research.
-
List item
Programme - Workshop on the role of pharmacokinetic and pharmacodynamic measurements in the use of direct oral anticoagulants (PDF/103.79 KB)
First published: 16/10/2015
Last updated: 17/11/2015
EMA/681537/2015 -
List item
Workshop - the role of pharmacodynamic and pharmacokinetic measurements in the use of direct oral anticoagulants: Background document (PDF/135.01 KB)
First published: 20/11/2015
Last updated: 20/11/2015
EMA/746962/2015 -
List item
Proceedings of the workshop on the role of pharmacokinetic and pharmacodynamic measurements in the use of direct oral anticoagulants (PDF/133.43 KB)
First published: 07/01/2016
Last updated: 07/01/2016
EMA/803589/2015 -
List item
List of participants - Workshop on the role of pharmacokinetic and pharmacodynamic measurements in the use of direct oral anticoagulants (PDF/122.38 KB)
First published: 07/01/2016
Last updated: 07/01/2016
EMA/772047/2015 -
List item
Presentation - DOACs: the patient perspective (Christine Dehn) (PDF/336.78 KB)
First published: 07/01/2016
Last updated: 07/01/2016 -
List item
Presentation - Challenging patients on DOACs and need for monitoring (Menno Huisman) (PDF/1.04 MB)
First published: 07/01/2016
Last updated: 07/01/2016 -
List item
Presentation - Management of DOAC in clinical praxis (Peter J Svensson) (PDF/5.08 MB)
First published: 07/01/2016
Last updated: 07/01/2016 -
List item
Presentation - What can we do now and what are the gaps in our knowledge? The direct thrombin inhibitor (dabigatran etexilate) (Marie Louise S. Christiansen) (PDF/285.33 KB)
First published: 07/01/2016
Last updated: 07/01/2016 -
List item
Presentation - Session 2: What can we do now and what are the gaps in our knowledge? The direct factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) (Antonio Gà³mez-Outes) (PDF/1.03 MB)
First published: 13/01/2016
Last updated: 13/01/2016 -
List item
Presentation - Session 3: the analytical part - Measuring the concentration of the direct thrombin inhibitor (dabigatran etexilate) (Franà§ois Mullier) (PDF/1015.5 KB)
First published: 07/01/2016
Last updated: 07/01/2016 -
List item
Presentation - Measuring concentrations of Rivaroxaban, Apixaban, Edoxaban: methods and challenges (Steve Kitchen) (PDF/517.45 KB)
First published: 07/01/2016
Last updated: 07/01/2016 -
List item
Presentation - NOAC future perspectives: academic perspective (Hugo ten Cate) (PDF/2.42 MB)
First published: 07/01/2016
Last updated: 07/01/2016 -
List item
Presentation - Future perspectives: how to better use the available data, how to fill the gaps in our knowledge about PK/PD, future ways on how knowledge can be obtained (Jà¶rg Kreuzer) (PDF/252.1 KB)
First published: 07/01/2016
Last updated: 07/01/2016 -
List item
Presentation - Industry perspective: Bayer/Janssen (Scott D. Berkowitz) (PDF/874.78 KB)
First published: 07/01/2016
Last updated: 07/01/2016 -
List item
Presentation - Industry perspective: Pfizer - Eliquis® (apixaban) (PDF/228.82 KB)
First published: 07/01/2016
Last updated: 07/01/2016 -
List item
Presentation - Session 4: future perspectives - What could be done? Industry perspective (Daiichi Sankyo) (PDF/371.72 KB)
First published: 07/01/2016
Last updated: 07/01/2016